Publication
Insurance regulation in Asia Pacific
Ten things to know about insurance regulation in 19 countries.
Canada | Publication | July 2022
Our 2022 Guide to Canada’s Pharmaceutical Intellectual Property Regime is a convenient all-in-one reference to the important legal and regulatory regimes governing pharmaceuticals in Canada.
The Guide provides a detailed review of the key regimes, including:
We are honoured that the Guide includes a Foreword by our partner, The Right Honourable Brian Mulroney. During his tenure as the 18th Prime Minister of Canada, Mr. Mulroney championed a series of significant legislative reforms to improve protections for pharmaceuticals that continue to operate today. The COVID-19 pandemic has highlighted the importance of fostering investment in research, development and manufacturing by the innovative pharmaceutical industry in Canada. Norton Rose Fulbright’s pharmaceuticals and life sciences team understands the innovative pharmaceutical industry and will continue to work with innovators to defend their rights and maintain the benefits they bring to all Canadians.
We hope this Guide will assist in navigating the complex challenges of this rapidly evolving field.
Publication
Ten things to know about insurance regulation in 19 countries.
Publication
A recent decision made by the UK's Advertising Standards Authority (ASA) brings into sharp relief the challenges for airlines to strike a balance between marketing their sustainability efforts in an understandable and compelling way, whilst avoiding criticism for “greenwashing”.
Publication
On November 28, 2023, the European Commission (EC) adopted its first list of Projects of Common Interest (PCIs), i.e., projects within the EU territory, and Projects of Mutual Interest (PMIs), i.e., projects connecting the EU with other countries, including 166 projects implementing the European Green Deal.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025